Addex Therapeutics Ltd (ADXN) on Friday said Phase 2a feasibility study of dipraglurant in patients with blepharospasm did not meet all of its goals.
Blepharospasm is characterized by involuntary contractions of the eyelid muscles resulting in visual disturbance or functional blindness.
The primary objective of the Phase 2a feasibility study that enrolled 15 patients, was to evaluate the safety and tolerability of dipraglurant in patients with blepharospasm.
Addex said the study was inconclusive and did not meet all of its objectives.
Another Phase 2B/3 study of dipraglurant for the treatment of Parkinson's disease levodopa induced dyskinesia remains on track to report data in the first half of 2023, the company added.
Dipraglurant is a metabotropic glutamate receptor subtype 5 negative allosteric modulator, or mGlu5 NAM, the company said.
For comments and feedback contact: editorial@rttnews.com
Business News